Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction of Cure in Early Arthritis
NL-OMON54053Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of baricitinib and methotrexate in undifferentiated arthritis (UA) and autoimmune arthritis (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Decrease in disease activity at 3 months. Started Feb 2021; status: completed.
02
Drugs
baricitinibmethotrexate
03
Conditions
undifferentiated arthritis (UA)autoimmune arthritis
Beyond the preview
Go deeper on NL-OMON54053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54053.